Apellis Pharmaceuticals recently announced post hoc analysis data of the GALE extension study. This new data is the result of five years of patients continuously treated with SYFOVRE (pegcetacoplan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback